Literature DB >> 25263321

A study for proposal of use of regulatory T cells as a prognostic marker and establishing an optimal threshold level for their expression in chronic lymphocytic leukemia.

Alakananda Dasgupta1, Manoranjan Mahapatra, Renu Saxena.   

Abstract

Although regulatory T cells (Tregs) have been extensively studied in chronic lymphocytic leukemia, there is no uniform guideline or consensus regarding their use as a prognostic marker. This study describes the methodology used to develop an optimal threshold level for Tregs in these patients. Treg levels were assessed in the peripheral blood of 130 patients and 150 controls. Treg frequencies were linked to established prognostic markers as well as overall survival and time to first treatment. The cut-offs for Treg positivity were assessed by receiver operating characteristic (ROC) analysis. A cut-off of 5.7% for Treg cell percentage and of 35 cells/μL for absolute Treg cell count were determined as optimal in patients with CLL along with a median Treg percentage of 15.5% used to separate patients with low- and high-risk disease. The experiments presented here will possibly aid in the use of Treg frequencies as a potential prognostic marker in CLL.

Entities:  

Keywords:  Chronic lymphocytic leukemia; Kaplan–Meier estimates; optimal cut-off; overall survival; prognostic marker; receiver operating characteristic analysis; regulatory T cell; time to first treatment

Mesh:

Substances:

Year:  2014        PMID: 25263321     DOI: 10.3109/10428194.2014.966245

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  7 in total

Review 1.  SLAMF6 in health and disease: Implications for therapeutic targeting.

Authors:  Burcu Yigit; Ninghai Wang; Roland W Herzog; Cox Terhorst
Journal:  Clin Immunol       Date:  2018-10-23       Impact factor: 3.969

2.  Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses.

Authors:  Alak Manna; Timothy Kellett; Sonikpreet Aulakh; Laura J Lewis-Tuffin; Navnita Dutta; Keith Knutson; Eduardo Chini; Javier Pinilla-Ibarz; Nicole Lamanna; Rami Manochakian; Fabio Malavasi; Taimur Sher; Asher A Chanan-Khan; Sikander Ailawadhi; Aneel Paulus
Journal:  Blood Adv       Date:  2020-05-26

Review 3.  Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies.

Authors:  Giovanni D'Arena; Candida Vitale; Marta Coscia; Agostino Festa; Nicola Matteo Dario Di Minno; Vincenzo De Feo; Michele Caraglia; Gioacchino Calapai; Luca Laurenti; Pellegrino Musto; Giovanni Di Minno; Daniela Fenoglio
Journal:  J Immunol Res       Date:  2017-12-21       Impact factor: 4.818

4.  T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers.

Authors:  Marzia Palma; Giusy Gentilcore; Kia Heimersson; Fariba Mozaffari; Barbro Näsman-Glaser; Emma Young; Richard Rosenquist; Lotta Hansson; Anders Österborg; Håkan Mellstedt
Journal:  Haematologica       Date:  2016-12-07       Impact factor: 9.941

Review 5.  Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia.

Authors:  Valentina Griggio; Francesca Perutelli; Chiara Salvetti; Elia Boccellato; Mario Boccadoro; Candida Vitale; Marta Coscia
Journal:  Front Immunol       Date:  2020-11-18       Impact factor: 7.561

6.  Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.

Authors:  Nina Kreuzberger; Johanna Aag Damen; Marialena Trivella; Lise J Estcourt; Angela Aldin; Lisa Umlauff; Maria Dla Vazquez-Montes; Robert Wolff; Karel Gm Moons; Ina Monsef; Farid Foroutan; Karl-Anton Kreuzer; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2020-07-31

7.  Deregulation of SOCS5 suppresses dendritic cell function in chronic lymphocytic leukemia.

Authors:  Patricia A Toniolo; Suhu Liu; Jennifer E Yeh; Darwin Q Ye; José Alexandre M Barbuto; David A Frank
Journal:  Oncotarget       Date:  2016-07-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.